Siemens Healthineers company Varian has completed enrollment for its FAST-02 (Flash Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax) clinical trial.
The study targets thoracic bone metastases and "represents a significant step toward bringing this investigational radiotherapy treatment into clinical practice," according to the firm. It is being conducted at Cincinnati Children's Hospital/UC Health Proton Therapy Center in Ohio and includes 10 patients; it builds upon findings from the company's FAST-01 trial, which evaluated clinical workflow feasibility of Flash therapy and treatment-related side effects for participants with bone metastases in the extremities, Varian said.
FAST-02's principal investigator is John Perentesis, MD, director of the Cancer and Blood Disease Institute at Cincinnati Children's Hospital. Its co-lead investigator is Emily Daugherty, MD, associate professor of radiation oncology at the University of Cincinnati Cancer Center.
